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AbsTrACT
Objective This study aimed to demonstrate that large-
scale visual field (VF) data can be extracted from electronic 
medical records (EMRs) and to assess the feasibility of 
calculating metrics from these data that could be used to 
audit aspects of service delivery of glaucoma care.
Method and analysis Humphrey visual field analyser 
(HFA) data were extracted from Medisoft EMRs from five 
regionally different clinics in England in November 2015, 
resulting in 602 439 records from 73 994 people. Target 
patients were defined as people in glaucoma clinics with 
measurable and sustained VF loss in at least one eye 
(HFA mean deviation (MD) outside normal limits ≥2 VFs). 
Metrics for VF reliability, stage of VF loss at presentation, 
speed of MD loss, predicted loss of sight years (bilateral VF 
impairment) and frequency of VFs were calculated.
results One-third of people (34.8%) in the EMRs had 
measurable and repeatable VF loss and were subject 
to analyses (n=25 760 patients). Median (IQR) age and 
presenting MD in these patients were 71 (61, 78) years 
and −6 (–10, –4) dB, respectively. In 19 264 patients 
with >4 years follow-up, median (IQR) MD loss was −0.2 
(−0.8, 0.3) dB/year and median (IQR) intervals between VF 
examinations was 11 (8, 16) months. Metrics predicting 
loss of sight years and reliability of examinations varied 
between centres (p<0.001).
Conclusion This study illustrates the feasibility of 
assessing aspects of health service delivery in glaucoma 
clinics through analysis of VF databases. Proposed metrics 
could be useful for blindness prevention from glaucoma in 
secondary care centres.
InTrOduCTIOn
Electronic medical records (EMRs) have 
potential to form a repository of data on 
patient encounters that can be directly used 
in research and clinical audit.1 The latter 
can be used as a first step towards improving 
health service delivery and improving patient 
care. Indeed, it is only possible to gauge 
improvements in a process after it has been 
measured in the first place.
Glaucoma clinics in Hospital Eye Services 
(HES) in England handle more than 1 million 
patient visits per year.2 3 Most of these visits 
are for monitoring people with established 
glaucoma. Once diagnosed, all patients with 
glaucoma require lifelong monitoring so that 
any worsening of disease can be detected and 
treatment intensified accordingly. Patient 
management focuses on monitoring the 
visual field (VF), assessment of the optic nerve 
and measurement of the intraocular pressure 
(IOP). The latter is critical because it is the 
only modifiable risk factor for the condition 
worsening (progression).4 Research evidence 
from clinics in England suggest measures of 
IOP are the main determinant of how often a 
patient is monitored over a period of time.5 6 
In contrast to IOP, a measurement of the VF 
is the closest surrogate to what matters to the 
patient in the glaucoma clinic, that is, pres-
ervation of their vision.7 VF monitoring is 
therefore recognised to be critically important 
for the clinical management of the patient but 
it is also perceived to be difficult to do unless 
it is well implemented.8–10 The computerised 
technology used to measure VFs (standard 
Key messages
What is already known about the subject?
 ► Electronic medical record (EMR) systems are rou-
tinely used for patient management in eye clinics. 
Data from these EMRs have been used effectively in 
clinical services (such as cardiovascular healthcare) 
to audit/manage both patients and clinics, but less 
so in ocular healthcare.
What are the new findings?
 ► The potential use of visual field data for audit in 
glaucoma was demonstrated by successful down-
load and aggregated analysis of an anonymised data 
extract. We propose several metrics that can be used 
to monitor various aspects of glaucoma clinics. We 
compare these metrics in five glaucoma clinics in 
England.
How might these results change the focus of 
research or clinical practice?
 ► This type of electronic monitoring of glaucoma ser-
vice delivery could be used to assess, in real time, 
how a glaucoma clinic is performing and highlight 
potential areas for improvement. Identification of 
patients at high risk of blindness could facilitate tar-
geting of care towards those most at need.
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Table 1 Total number of visual fields per centre. Each 
centre is simply labelled 1–5 and represented by a specific 
colour. This colour coding is used throughout this report 
(every centre had data recorded between April 2000 and 
March 2015 apart from centre 5 where data were first 
recorded in May 2000).
Centre 1 Centre 2 Centre 3 Centre 4 Centre 5
People, n 3423 8459 27 921 18 636 15 555
VF records, 
n
16 162 65 355 285 552 113 847 121 523
VF, visual field.
automated perimetry (SAP)) has been in clinics for 
20–30 years and has remained largely unchanged. Data 
from SAP are stored electronically, often in an EMR. 
These records, which are likely to be historically rich, 
should be amenable to easy electronic auditing. There-
fore, at different clinical centres it might be possible, for 
example, to audit measures of disease severity (VF loss) 
of patients at diagnosis. Moreover, it might be possible to 
audit speed at which patients in different clinics might 
be losing vision and, for example, whether frequency of 
VF monitoring is consistent across clinics. It is these ideas 
that we explore in this report.
The National Ophthalmology Database (NOD) was 
established under the auspices of the Royal College of 
Ophthalmologists (RCOphth) in 2010. The NOD aimed 
to collate pseudonymised data collected as a by-product of 
routine clinical care using EMR systems for the purposes 
of national audit, research and establishing meaningful 
measures for revalidation of ophthalmologists.11 In 
2014, the Healthcare Quality Improvement Partnership 
(HQIP) commissioned NOD to do a feasibility study to 
investigate the use VF data to audit activity in glaucoma 
clinics. The results of the study are reported here with 
the specific aim of examining the viability of extracting 
meaningful metrics of health service delivery that might 
in the future allow comparison between glaucoma clinics.
MeTHOds
VF data were extracted from the Medisoft EMR system 
(Medisoft, Leeds, UK) from five regionally different 
National Health Service (NHS) Hospital Trust glaucoma 
clinics in England. The extraction was done in November 
2015 and data transferred to the RCOphth NOD. All 
patient data were anonymised and subsequently trans-
ferred to a single secure database held at City university. 
For the purpose of this report, the five centres are anony-
mised. No other clinical data were used in this study 
apart from patient’s age, gender and the dates of the 
VF examinations. Subsequent analyses of the data were 
approved by a research ethics committee of City, Univer-
sity of London; the study adhered to the Declaration of 
Helsinki and the General Data Protection Regulation of 
the European Union. The database material contained 
602 439 separate VF records from 73 994 people (table 1) 
recorded between April 2000 and March 2015.
Patient involvement
This research was done without patient involvement. 
Patients were not invited to contribute to the editing 
or writing of this document. Patients were not asked 
to comment on the study design, consulted to develop 
patient relevant outcomes or to interpret the results.
Inclusion and exclusion criteria
SAP in these clinics, and most others in England, is 
routinely performed on a Humphrey visual field analyser 
(HFA, Carl Zeiss Meditec, Dublin, California, USA). Only 
VFs recorded on the HFA using a Goldmann size III stim-
ulus with a 24-2 test pattern acquired with the Swedish 
Interactive Testing Algorithm (SITA Standard or SITA 
Fast) were included, reducing the aggregated database 
to 576 615 VFs from 71 361 people. SITA fast is commonly 
used in clinics in England. (Although SITA Standard is a 
more precise testing algorithm than SITA Fast at lower 
VF sensitivities, it is unlikely to make a sizeable difference 
to improving the time to detect VF progression.12) In our 
study population, 83% of the recorded VFs were SITA 
Fast and the rest were SITA Standard.
For the purpose of this report, our study population was 
defined as people in glaucoma clinics with measurable 
and sustained VF loss in at least one eye. This definition 
aims to exclude people suspected of having possible glau-
coma (glaucoma suspects) and people with normal VFs 
and raised eye pressure (ocular hypertension (OHT)). 
Therefore, patients were only included if they had a VF 
with an HFA mean deviation (MD) flagged as outside the 
95% normative limits in the HFA VF analysis software in 
at least one eye. (MD is a standard measure of the overall 
severity of VF loss, relative to healthy peers, with more 
negative values indicating greater VF loss.) Moreover, this 
proxy criterion for measurable VF loss had to be satisfied 
for both of the first two VFs recorded in the clinic; this 
was done in order to improve the precision of the esti-
mate of an individual likely to have real VF loss at their 
presentation to secondary care. The number of patients 
satisfying these criteria expressed as a percentage of the 
total number of people with a VF record was calculated. 
This can be thought of as a simple count of people in 
clinics with actual VF loss at presentation to secondary 
care (diagnosis) as opposed to, for example, being a glau-
coma suspect, a false-positive referral or having OHT.
Metrics for assessing service delivery
Six different metrics were calculated to characterise and 
estimate aspects of patient monitoring and outcomes in 
the clinics.
Age at presentation was estimated by the age of the 
patient (years) at the time of their first VF record.
Reliability of VFs was estimated by using the HFA 
false-positive (FP) measure. It is accepted that HFA FP 
is a useful measure of a reliable examination.13 The HFA 
flags VFs as unreliable if there are more than 15% FP 
errors. Percentage of all VFs considered as unreliable due 
to FP errors was therefore determined for each centre.
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Stage of VF loss at presentation was estimated by MD 
in the worse eye (the one with the more negative MD) at 
the second VF examination. The second VF was used to 
ameliorate the bias of the perimetry learning effect.14 15 
We chose the worse eye as a surrogate of the most ‘detect-
able’ level of VF loss at the stage of case finding in primary 
care. Patients with MD worse than −12 dB in this eye were 
defined as having advanced VF loss. Patients with MD 
better than −6 dB in this most affected eye were defined 
as having early VF loss, with all other patients classified 
as having moderate VF loss. These VF criteria have been 
used in health economic investigations of service delivery 
of glaucoma.16 17 The proportion of patients within each 
of these three categories (early, moderate, advanced) can 
be summarised in a traffic-light waffle plot (green, yellow, 
red) for each centre.
Next, a subset of the study patients with sufficient 
series of VF examinations were defined as those with at 
least five VFs recorded over a period of 4 or more years. 
This subset of data were used for three more metrics 
summarising patient follow-up activity at each clinic.
Speed (rate) of VF loss in clinics was determined by 
using simple linear regression of MD against time of 
follow-up (dB/year) and was only calculated in patients 
with series of data. The first VF examination in each 
series was removed to account for perimetric learning 
effects.
Risk of VF loss blindness in clinics was estimated by a 
Loss of Sight Years (LSY) metric as described elsewhere.18 
In short, LSY estimates the number of years that a patient 
will have bilateral VF loss worse than MD of −22 dB 
(binocular VF impairment) in their predicted remaining 
lifetime.19 The metric considers rate of VF loss in both 
eyes and the patient’s residual life expectancy based on 
age and sex as reported in UK Office of National Statis-
tics.20 Residual life expectancy takes into account that 
a person aged, for example, 80 years is more likely to 
live to age 81 years than someone aged 70 years and is 
a useful measure of relative life expectancy. For patients 
with two eligible eyes with series of VF data, we deter-
mined whether LSY would be predicted to be longer than 
3 years. We then calculated the percentage of patients in 
each centre with this attribute.
Frequency of VF examination in clinics was simply 
estimated as the average interval (months) between 
recorded VF examinations during the follow-up period 
in those patients with series of VF data.
Summary measures and distributions of these metrics 
were evaluated and compared for the five glaucoma 
clinics. We used medians and IQRs along with conser-
vative non-parametric tests to make simple, illustrative 
comparisons between clinics. All analyses were done 
using R (R Development Core Team, R: A Language and 
Environment for Statistical Computing, R Foundation 
for Statistical Computing, Vienna, Austria, URL: http://
www. R- project. org, 2008).21
resulTs
Application of the inclusion and exclusion criteria 
resulted in 223 379 VFs from 25 760 patients. Therefore 
65.2% (n=48 234) of people were excluded because 
they only had one VF examination or normal VFs in 
both eyes in their first or second VF examination. These 
people were excluded from further analysis. Series of VFs 
(more than 4 years of follow-up) were available for 19 264 
patients. Summary measures of the metrics for assessing 
glaucoma service delivery for the five centres (and the 
aggregate data) are given in table 2.
There was a statistically significant difference in the 
median age at presentation between the centres (p<0.001; 
Kruskal-Wallis test). Centre 1 had slightly older patients 
with little difference between the other centres. There 
was also a statistically significant difference between 
centres for percent of unreliable VFs (p<0.001; χ2 test). 
Centre 1 (despite having older test takers) returned the 
lowest proportion of unreliable VFs. Differences between 
centres were generally small. Yet, for example, the rate of 
unreliable VFs recorded at centre 3 was 1.7 times higher 
than that of centre 1 (95% CI for the relative risk of 1.4 
to 1.9). It is noteworthy that around 1 in 20 VF exam-
inations were unreliable according to this proxy measure 
across all centres.
Stage of VF loss at presentation is also summarised 
as a series waffle (traffic light) plots for each centre in 
figure 1. Centre 1 had notably more patients presenting 
with advanced VF loss when compared with the other 
centres. (Note this value summarises percent with 
advanced loss for those who present with some sort of VF 
loss. The value would be lower if the denominator was all 
people in the clinics.22)
Speed (rate) of VF loss in the five clinics are summarised 
as distributions in figure 2. The distributions were gener-
ally similar with the exception of centre 1 (and to a 
lesser extent centre 2); these distributions exhibited 
much heavier tails which means there were more eyes 
experiencing faster speed of loss VF loss at these centres 
compared with the others.
Risk of VF loss blindness as estimated by percentage 
of patients predicted to have LSY >3 years was slightly 
greater in centre 2 (12.9%) compared with the other 
centres and this was statistically significant (p<0.001; 
Kruskal-Wallis test).
Frequency of VF examination at the five clinics is 
summarised by distributions of the time interval in 
months between VF tests in figure 3. Centre 4 had a 
noteworthy longer median time interval between VF tests 
(15.4 months) compared with the other centres and this 
was statistically significant (p<0.001; Kruskal-Wallis test).
One way of visualising speed of VF loss in clinics is to 
use a Hedgehog plot.18 One of these is shown for centre 
1 in figure 4.
dIsCussIOn
This work confirms that routinely collected VF data from 
glaucoma clinics can be downloaded, aggregated and 
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Table 2 This table shows the summary measures of a number of metrics across the five centres (and a total column). The six 
main metrics highlighted in the Methods section are given in bold font. Median (and IQR) values or percentages are reported 
as summary measures.
Centre 1 Centre 2 Centre 3 Centre 4 Centre 5 TOTAL
Patients with VF 
loss, n
1373 2404 11 589 5713 4681 25 760
VFs, n 7813 19 654 121 939 36 011 35 737 223 379
Sex (% men) 45.6 45.2 47.1 47.7 44.8 46.5
Median (IQR) 
Age (years) at 
presentation
75 (67, 80) 71 (61, 78) 71 (61, 78) 71 (62, 79) 69 (58, 77) 71 (61, 78)
% of unreliable VFs 3.0 4.4 5.1 4.3 4.1 4.6
Median (IQR) MD at 
presentation (dB)
−6.5 (−11.7, -3.9) −5.8 (−10.6, −3.6) −5.7 (−10.1, −3.6) −5.4 (−9.9, −3.5) −5.4 (−9.9, −3.5) −5.6 (−10.2, −3.6)
% patients with 
advanced VF loss 
at presentation
29.6 25.0 24.2 23.0 22.8 24.0
Patients* with VF 
series >4 years, n
843 1786 9208 3917 3480 19 264
Median (IQR) MD 
loss per year (dB/
year)*
−0.37 (−1.2, 0.32) −0.26 (−0.90, 0.20) −0.23 (−0.83, 
0.21)
−0.19 (−0.81, 
0.27)
−0.10 (−0.71, 0.37) −0.21 (−0.83, 0.26)
% Patients LSY 
>3 years
12.5 12.9 11.8 10.1 10.0 11.2
Median (IQR) 
interval between 
VFs (months)
12.6 (8.6, 18.1) 10.3 (7.6, 13.6) 9.5 (7.2, 13.0) 15.4 (11.5, 21.1) 12.3 (9.6, 16.5) 11.2 (8.1, 15.8)
LSY, Loss of Sight Years; MD, mean deviation; VF, visual field.
anonymised from an EMR and be made available for anal-
ysis. This has previously been done for research purposes 
yet, here we illustrate how it could be done to potentially 
monitor and compare health service delivery at different 
glaucoma clinics.12 19 22–24 For this exercise, assessments 
were done on anonymised centres with a key point of 
this work showing that this approach is feasible for future 
implementation. We did not assess the logistics of the VF 
data extraction, which in this instance was carried out as 
part of the NOD work commissioned by HQIP. We have 
shown that assessment of VF records in glaucoma clinics 
could provide a first step towards quality improvement of 
services; this is a novel idea. For example, we have demon-
strated how VF metrics of late presentation of glaucoma, 
or speed of loss of VF in people in glaucoma clinics 
during follow-up could be easily summarised for a clin-
ical centre. We also have shown how it might be possible 
to compare the reliability and use of VF measurement 
between centres—for instance, it is feasible to identify 
centres that are doing more or fewer VF examinations 
compared with others. The latter is important because it 
has been shown previously, via health economic model-
ling of retrospective data, that optimising use of VF 
resources could improve clinical management of patients 
and save money at the same time.3 Since VF data can be 
held in EMRs this makes them amenable to automated 
and live analysis. Our feasibility study indicates that this 
approach could be used to monitor what happens to 
people in different glaucoma clinics in real time. Assess-
ment of quality improvement of glaucoma services with 
an implementation of this idea could be the subject of 
future work.
The results from this report illustrate the feasibility 
of calculating metrics for assessing service delivery 
between centres using VF records alone. Nevertheless, 
some discussion about the differences in these metrics 
between the five anonymous centres is worthwhile. For 
example, centre 1 had more patients presenting with 
advanced VF loss and had more patients losing VF at 
a faster speed than other centres. These variables are 
highly associated in people with glaucoma and are, in 
turn, positively associated with older age.3 24 25 It is note-
worthy that patients in centre 1 were generally older than 
those in the other centres and this might, at least in part, 
explain these observations. Still, our chosen metric for 
risk of VF loss blindness as estimated by percentage of 
patients predicted to have LSY >3 years was 12.5% in 
centre 1. This observation underlines the importance 
of preventing late detection of VF loss for prevention of 
avoidable blindness.19
Our report reveals some other interesting subsidiary 
findings. Our population for this report is people with 
measurable VF loss in glaucoma clinics (at least two VFs 
with actual VF loss as measured by MD). These inclusion 
criteria reduced our sample by 65.2%. In other words, 
around two-thirds of people with HFA 24-2 VF records 
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Figure 1 A traffic-light (waffle) plot showing the 
classification of visual field (VF) loss of newly presenting 
patients in each of the five centres. Each square represents 
1% of the patients being classified as early (green), moderate 
(yellow) or advanced (red) VF loss on presentation.
Figure 2 A plot showing the distribution of the speed 
of mean deviation (MD) loss (dB/year) in each of the five 
centres. Each line represents one of the centres. The 
distribution curves are obtained by using kernel density 
estimation to fit a smoothed curve to a histogram. Centre 
1 (red) has a heavier tail compared with the other centres, 
indicating a higher proportion of patients with higher speeds 
of loss. Centre 1 also has a lower kurtosis (tail-to-peak ratio) 
and more negative skewness than the others. The coloured 
symbols on the x-axis indicate the median value for each 
centre (see table 2).
Figure 3 A plot showing the distributions of the time 
interval between patient visits (in months) in each of the five 
centres. Each line represents one of the centres. Centre 4 
is more positively skewed, indicating a higher proportion of 
patients with longer intervals between visits. The coloured 
symbols indicate the median time interval between visits for 
each centre (see table 2).
Figure 4 A hedgehog plot showing the mean deviation loss 
over time of each eye in centre 1. Eyes highlighted in red 
indicate a speed of loss worse than −1.5 dB/year. The region 
marked in blue is a threshold for a severely impaired visual 
field. More detail on these plots can be found in Bryan et al.18
in these data sets had single ‘one-off’ VFs or had normal 
VFs at presentation to the clinics. This figure illustrates 
the huge volume of likely false-positive glaucoma refer-
rals, glaucoma suspects and ocular hypertensive that 
glaucoma clinics deal with on a daily basis. Moreover, 
we found that around 1 in 20 VFs are recorded with 
reliability indices outside normal limits. In addition, 
the median interval between VF tests in people being 
followed over time was 11.2 months and as high as 15.4 
months in one centre. This supports previous findings 
that annual VF testing is the norm for most patients in 
glaucoma clinics in England.6 Heath economic model-
ling has highlighted the benefits of stratifying patients 
to more or less VF monitoring based on age and stage 
of disease at diagnosis; a prospective study is needed to 
prove these findings.3
Using EMRs for research or audit is not a new idea, 
having been implemented in many fields of medicine to 
study diseases such as diabetes, heart failure, cancer and 
asthma.26 In eye clinics EMRs have been used for audit 
of cataract surgical outcomes but importantly also have 
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potential for making healthcare delivery more efficient 
by facilitating more streamlined clinical work flow, better 
patient management and improved data tracking.11 27–32 
However, ideas and implementation are different entities 
and meaningful use of EMRs in ophthalmology is still a 
work in progress.33–35 At present, certainly in clinics in 
England, there are challenges about how clinical data 
are recorded, archived and stored. Moreover, issues such 
as non-collated data sets, duplicate IDs and differing 
databases add to the challenge of moving towards 
comprehensive use of EMRs.
Our approach to the concept of assessing service delivery 
in glaucoma clinics has several strengths. In theory, VF 
records should be easily stored on EMRs, making them 
amenable to easy extraction, analysis and audit. Whether 
this happens in practice is dependent on the motivation 
of implementing electronic archiving of VF examinations 
and use of EMRs in HES. Another rational for using VF 
metrics is their relevance to measuring vision. IOP is the 
only modifiable risk factor for glaucoma progression and 
is crucial to patient management but VF metrics will best 
estimate the status of people’s vision loss in the clinic. Our 
approach does not consider everyone in glaucoma clinics 
but centres on those with a proxy measure of sustained 
VF loss. These patients are at higher risk of further signif-
icant vision loss in their lifetime compared, for example, 
with people with OHT.19 33–35
There are limitations to the ideas that we report in 
this study. The main problem is reliance on the VF data 
alone. A more complete assessment of what is happening 
in a glaucoma clinic would be achieved by considering 
exact diagnosis, treatment regimens, IOP, optic nerve 
head characteristics, individual patient history or other 
risk factors. For example, much can be learnt about what 
is happening in glaucoma clinics by reviewing reposito-
ries of data on prescribed medications.36 However, EMRs 
need an established and standardised minimum data set 
for glaucoma care and this is the subject of future work. 
Our idea will also be limited to how well VF records can 
be archived at a centre. The five sites chosen for this study 
were all EMR enabled and known to run large glaucoma 
services with aggregated electronic VF databases. Alterna-
tive options could include separate data extractions from 
individual machines with subsequent aggregation into a 
single database, but this would be time consuming and 
carry significant cost, in particular if these services were 
delivered in different settings such as outreach clinics.
There are also limitations to some of the metrics we 
have proposed for assessing service delivery. First, while 
MD is a useful summary measure of how much sensi-
tivity loss there is in a VF and particularly convenient to 
monitor changes over time, it is not a perfect measure for 
glaucomatous VF loss. MD can be affected by non-glau-
comatous changes such as a general reduction in VF 
sensitivity caused by, for example, cataract. Second, as 
noted previously, we only used the FP reliability index as a 
measure of patient test taking performance.13 Of course, 
this measure, or any other similar measure, would not 
capture patients failing to complete an examination or 
those excluded because of a previous failure to reliably 
conduct a VF examination. Third, our measure of “risk of 
blindness” (LSY) makes a number of assumptions around 
residual life expectancy and progression of VF loss being 
constantly linear. Finally, when comparing metrics it will 
also be important to consider some centres simply differ 
in terms of population factors (eg, racial and socioeco-
nomic profile) and audits using the methods proposed in 
our report would have to take this into account.
In conclusion, this study illustrates the feasibility of 
assessing some aspects of quality of care in glaucoma 
clinics through analysis of VF databases from EMR 
enabled centres. This approach, which is outcome 
focused, is a potentially useful method for assessing 
blindness prevention from glaucoma in secondary care 
centres. VF testing technology is standardised in the UK 
NHS, and although in many centres the electronic VF tests 
will be distributed across several VF testing machines, it is 
feasible to aggregate these fields into a central database 
located in each centre for central analysis. Ideally, such 
a central field database would reside within a specialty 
specific EMR implementation serving both clinical and 
quality assurance needs. Secondary benefits from such an 
approach would include the ability to more easily detect 
patients whose VF loss is progressing rapidly in order 
to intensify their treatment as well as detection of those 
patients whose VFs are stable who may require less inten-
sive monitoring once VF stability has been documented. 
By shifting focus towards those in most need, health 
services resources can be more effectively used. In the 
current NHS digital environment, a variety of challenges 
would need to be overcome in order to extend this audit 
approach into a national audit of vision preservation in 
people with glaucoma.
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